<DOC>
	<DOCNO>NCT01923584</DOCNO>
	<brief_summary>The purpose study evaluate effect EPI-743 patient Parkinson 's disease .</brief_summary>
	<brief_title>A Phase 2A Trial EPI-743 Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Diagnosis Parkinson 's disease 2 . Age 40 75 3 . Ambulatory without assistance 4 . Hoehn Yahr Scale score 1 3 5 . Patient able consent comply protocol requirement 6 . Abstention use Coenzyme Q10 , vitamin E , Azilect Idebenone two week prior enrollment course treatment EPI743 1 . Allergy EPI743 sesame oil 2 . Allergy vitamin E 3 . Clinical history bleed abnormal baseline PT/PTT 4 . Diagnosis neurologic disease 5 . Malignancy within past two year 6 . Pregnant plan become pregnant 7 . Concomitant ophthalmologic disease 8 . History stroke 9 . History brain surgery 10 . Inability undergo MRI scan MRS 11 . Hepatic insufficiency LFTs great two time upper limit normal 12 . Renal insufficiency require dialysis 13 . End stage cardiac failure 14 . Fat malabsorption syndrome preclude drug absorption 15 . Use anticoagulant medication , azilect</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>